Navigation Links
Mayo Clinic researchers reveal treasure trove of genes key to kidney cancer
Date:7/1/2014

JACKSONVILLE, Fla. A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, from 72 patients has uncovered 31 genes that are key to development, growth and spread of the cancer, say researchers from Mayo Clinic in Florida. Eight of these genes had not been previously linked to kidney cancer, and six other genes were never known to be involved in any form of cancer.

MULTIMEDIA ALERT: Video and audio are available for download on the Mayo Clinic News Network.

Their study, in the journal Oncotarget, is the most extensive analysis to date of gene expression's role in ccRCC tumor growth and metastasis. The ccRCC subtype accounts for 80 percent of all kidney cancer cases.

This study is a thorough analysis, because overexpressed genes were functionally tested in kidney cancer cells to ensure they were important to some aspect of the cancer process, says the study's senior investigator, molecular biologist, John A. Copland, Ph.D.

"The power of this study is that we looked at genes discovered to be over-expressed in patients' tumors and determined their function in kidney cancer, which has not been done on a large scale before," he says. "This is a seminal step in identifying key pathways and molecules involved in kidney cancer so that specific therapies that target these new genes can be developed to treat this cancer."

This kidney cancer is one of the top 10 solid cancers in the U.S. Researchers expect 60,000 new cases to be diagnosed this year, with 13,000 deaths. While the prognosis for kidney cancer that has not spread is good, patients with advanced or metastatic cancer will develop drug resistance. Patients with untreated metastatic disease have a five-year overall survival rate of less than 10 percent.

The research team, which includes Mayo graduate student and lead author Christina von Roemeling, has already published several studies identifying some of the genes they discovered in the genetic analysis. In considering the importance of these discoveries to patients, they decided to publish all the genes at once in Oncotarget.

"We are releasing these discoveries to the scientific community so that a large effort can be mounted to find out more about these genes and how they can be effectively targeted," Dr. Copland says. "We owe patients speedy research that focuses on new treatments to save lives."

Targeted therapies used now to treat kidney cancer are often toxic, he adds.

"The study findings represent a very major advancement in therapeutic target identification for ccRCC and open new avenues for drug discovery and development. Novel therapeutic agents acting on these new targets should bring about a significant improvement in the prognosis of ccRCC patients," says co-author and Mayo oncologist Han Tun, M.D.

The researchers examined an equal number of samples (72) of normal kidney and kidney cancer tissues. They looked at over- and under-expression of RNA from the tissue, as well as protein production because genes express RNA to produce protein. They found almost 6,000 genes that fit that description. They isolated and tested 195 genes that are consistently elevated across patient samples. The researchers then narrowed the "hit" list to 31 after they tested each in living cancer cells to see if these genes contributed to either growth or spread of the tumor.

"We also found genes with other functions that are key to kidney cancer survival, such as inflammation. Another found gene is linked to angiogenesis, the production of new blood vessels to support a tumor. This is a novel discovery," says von Roemeling. "It is particularly important because ccRCC is well known for being a very angiogenic cancer.

"In addition to the potential of these genes and gene products to help us design new drugs, they could also serve as biomarkers for accurate diagnosis," she says. "It really is a treasure trove for future research on kidney cancer."


'/>"/>

Contact: Kevin Punsky
904-953-0746
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
2. First targeted nanomedicine to enter human clinical studies
3. Clinical insight improves treatment with new lung cancer drug
4. Clinical news alert from the American Academy of Orthopaedic Surgeons
5. Mayo Clinic launches whole genome breast cancer study
6. Mayo Clinic offers newly approved treatment for acid reflux disease
7. NYU Langone experts present research, clinical advances at neurosurgeons meeting
8. Mayo Clinic breast cancer study finds new type of mutation
9. Kroenke honored for outstanding contributions in clinical research training
10. Awards celebrate clinical research that can improve health and alleviate suffering
11. Association for Psychological Science, SAGE launch Clinical Psychological Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2019)... ... November 14, 2019 , ... BioInformatics Inc., part of Science and Medicine Group, ... that 7 companies have been nominated for a Life Science Industry Award ... the Life Science Industry Awards have recognized manufacturers of the “tools of science” that ...
(Date:11/12/2019)... ... ... AI for preventable harm analytics leader Jvion today announced that Jvion was included ... AI”, which provides a “tip of the spear” analysis of the healthcare AI market. ... complete a full KLAS analysis, Jvion was featured as having “by far the largest ...
(Date:11/12/2019)... , ... November 12, 2019 , ... ... and compliance management, today announced the release of new features for custom branding. ... platform interface and emails to match their physical brand attributes. Customizable attributes include ...
(Date:11/11/2019)... ... November 11, 2019 , ... Last year’s expo was a resounding success ... box buyers like Costco, Walmart, and GNC. Exhibitors included some of the biggest ... , This year, CBD.io and partners, are once again set to ...
(Date:11/9/2019)... ... November 08, 2019 , ... The Women’s Dermatologic Society (WDS) ... health concerns. The WDS Board of Directors appointed Molly Hinshaw, MD to fill the ... current March 2019-March 2020 term and will be presented to the membership as the ...
Breaking Medicine News(10 mins):
(Date:11/12/2019)... ... November 12, 2019 , ... MedMark Treatment Centers, a ... facility in the Cincinnati, OH suburb of Milford. MedMark Milford provides proven treatment ... clinic, located at 749C State Route 28 in Milford, is now accepting patients. ...
(Date:11/11/2019)... ... 11, 2019 , ... Oak Street Health , a network of primary ... centers in Greensboro and Charlotte, with an additional center in Charlotte under development. Committed ... model of care that emphasizes quality of care rather than quantity of services. Its ...
(Date:11/11/2019)... ... November 11, 2019 , ... MAPS and ... implementation of joint projects for the benefit of biomedical professionals in the ... professionals to leverage their roles in the research, development, and commercialization activities ...
Breaking Medicine Technology: